Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 16/20 | 0.45 |
| ▸ | NTSR2 | O95665 | 15/20 | 0.45 |
| ▸ | SORT1 | Q99523 | 14/20 | 0.45 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dusquetide SCHEMBL16677021 | 1.00 | NTSR1 (0.45) | NTSR1NTSR2SORT1XIAPPLK1 | |
| Dusquetide SCHEMBL29440126 | 0.86 | NTSR1 (0.55) | NTSR1NTSR2SORT1 | |
| SCHEMBL32679557 | 0.86 | NTSR2 (0.45) | NTSR1NTSR2SORT1XIAP | |
| SCHEMBL24452714 | 0.85 | KMT2A (0.44) | NTSR1NTSR2SORT1XIAP | |
| SCHEMBL30798320 | 0.84 | EPHA2 (0.43) | NTSR1NTSR2SORT1XIAPPLK1 | |
| SCHEMBL31256957 | 0.83 | XIAP (0.52) | NTSR1NTSR2SORT1XIAP | |
| SCHEMBL31461942 | 0.82 | NTSR1 (0.50) | NTSR1NTSR2SORT1PLK1 | |
| SCHEMBL31427004 | 0.82 | NRP1 (0.44) | NTSR1NTSR2SORT1XIAP | |
| SCHEMBL29410233 | 0.81 | EPHA2 (0.47) | NTSR1NTSR2SORT1 | |
| SCHEMBL31461877 | 0.81 | NTSR1 (0.43) | NTSR1NTSR2SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240415798-A1 | COMPOSITIONS AND METHODS FOR TREATING MUCOSITIS | ENZYCHEM LIFESCIENCES CORP (KR) | 2024-12-19 | — | — | US | claimed |
| EP-4419096-A1 | COMPOSITIONS AND METHODS FOR TREATING MUCOSITIS | Enzychem Lifesciences Corporation (KR) | 2024-08-28 | — | — | EP | claimed |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | CELLIX BIO PRIVATE LIMITED (IN) | 2024-02-20 | — | — | US | claimed |
| CN-116687784-A | Beauty soluble microneedle, preparation method and application | 安徽医科大学 | 2023-09-05 | — | — | CN | claimed |
| WO-2023067501-A1 | COMPOSITIONS AND METHODS FOR TREATING MUCOSITIS | ENZYCHEM LIFESCIENCES CORPORATION (KR) | 2023-04-27 | — | — | WO | claimed |
| WO-2022157587-A1 | A COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | WO | claimed |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | US | claimed |
| US-20220023419-A1 | INHIBITING INFLAMMATION | FRED HUTCHINSON CANCER CENTER | 2022-01-27 | — | — | US | claimed |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2026-05-14 | — | — | US | disclosed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-03-12 | — | — | US | disclosed |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | NOVARTIS PHARMA AG (CH) | 2025-12-23 | — | — | US | disclosed |
| CN-114126619-A | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2022-03-01 | — | — | CN | disclosed |
| US-20220023022-A1 | METHOD AND DEVICE FOR THE ENHANCEMENT OF TOPICAL TREATMENTS FOR ORAL MUCOSITIS AND OTHER ORAL CONDITIONS | E2BIO LIFE SCIENCES, LLC (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220023419-A1 | INHIBITING INFLAMMATION | FRED HUTCHINSON CANCER CENTER | 2022-01-27 | — | — | US | disclosed |
| US-11229578-B2 | Method and device for the enhancement of topical treatments for oral mucositis and other oral conditions | E2BIO LIFE SCIENCES, LLC (US) | 2022-01-25 | — | — | US | disclosed |
| US-20150148304-A1 | Novel Peptides and Analogs for Use in the Treatment of Macrophage Activation Syndrome | SOLIGENIX INC (US) | 2015-05-28 | — | — | US | disclosed |
| WO-2015061682-A2 | NOVEL PEPTIDES AND ANALOGS FOR USE IN THE TREATMENT OF MACROPHAGE ACTIVATION SYNDROME | SOLIGENIX, INC. (US) | 2015-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | NTSR1 59/4885NTSR2 54/4885SORT1 4244/4885 |
| US-20240415798-A1 | COMPOSITIONS AND METHODS FOR TREATING MUCOSITIS | IL18, MMP8, ELANE | NTSR1 3811/4885NTSR2 3966/4885SORT1 4222/4885 |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, IRF3, CGAS | NTSR1 1893/4885NTSR2 2640/4885SORT1 4850/4885 |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | NPR1, NGLY1, DDAH1 | NTSR1 60/4885NTSR2 114/4885SORT1 3626/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | NTSR1 113/4885NTSR2 315/4885SORT1 4138/4885 |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, CGAS, IRF3 | NTSR1 3913/4885NTSR2 4065/4885SORT1 4822/4885 |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | VNN1, LPL, HMGB1 | NTSR1 4139/4885NTSR2 4408/4885SORT1 4872/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | NTSR1 86/4885NTSR2 199/4885SORT1 4148/4885 |
| US-20150148304-A1 | Novel Peptides and Analogs for Use in the Treatment of Macrophage Activation Syndrome | VIP, IFNAR1, MYD88 | NTSR1 753/4885NTSR2 1609/4885SORT1 4540/4885 |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | VNN1, LPL, HMGB1 | NTSR1 4139/4885NTSR2 4408/4885SORT1 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.